


HANA ALABDULKARIM

Riyadh/Saudi Arabia 

+966541885885 

Hana_kareem@hotmail.com 

www.linkedin.com/in/alabdulkarim-hana 

Knowledgeable, dynamic, and determined leader with solid background and 15 years' experience in the healthcare Supply Chain Management and Health Economics field. Skilled in developing and implementing strategic plans, scientific evidence-based negotiation and project management skills. Lead by example, fostering an environment of open communications, motivation and engagement among management team and employees that deliver exceptional results—even with limited resources.

Experience

2019 - PRESENT

Director/Drug Policy and Economics Center/National Guard Health Affairs, Riyadh/Saudi Arabia

Key responsibilities of the center:

- Performing economic evaluation for pharmaceuticals considered for formulary addition and new healthcare technologies including new projects included for implementation in NGHA.
- Developing Drug use policies to guide the use of newly introduced costly pharmaceuticals.
- Negotiation with manufacturers and reviewing economic models submitted by manufacturers.
- Conducting economic analysis
- Participating in Health outcomes and economic research.

Key Achievements:

- Reduced total spending by 110 million SR (10% of the budget) in 2021 through building strategic partnerships, negotiation, cost containment initiatives, limiting indirect costs and shifting to good quality alternatives.
- Building the center vision, mission, strategic and operational plan for the center.
- Developing electronic signature system (TAWTHEEQ) for NGHA
- Developing several APPs including: risk-sharing agreement policy, Generic medications Policy and Biosimilar assessment policy.
- Several research award.

JAN 2023 - PRESENT

President /The Saudi Chapter of International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

JAN 2022 - PRESENT

Preceptor for residents and interns/Pharmacy College King Saud bin Abdulaziz University for Health Sciences

JAN 2016 – APRIL 2019

Pharmacoeconomist/ Drug Policy and Economics Center/National Guard Health Affairs,
Riyadh/Saudi Arabia

JAN 2015 – DEC 2015

Strategic Planning Senior Specialist, Strategic Planning Department, Corporate Planning &
Development Administration, King Fahad Medical City.

- Assisting in shaping the institution's overall strategic strategy
- Developing strategic plans to materialize strategy
- Assessing performance of different departments
- Conducting Research to identify threats and opportunities

MAR 2008 – JAN 2015

Planner / Supply – Pharmacy Coordinator, Pharmaceutical Supply Department, King Fahad
Medical City.

Education

Sep 2019

Health Economics and Outcomes Research Certificate /University of Washington, USA

Aug 2014

MSc Health Economic and Decision Modelling/University of Sheffield, UK

Aug 2013

Business, Law and Social Science Diploma /University of Sheffield, UK

Sep 2007

Bachelor of Pharmacy Science /King Saud University, KSA

Membership

- Member of the National Industrial Committee (Tayseer) at Ministry of Industry and Mineral Resources.
- Member of the National Pricing Committee at Saudi Food and Drug Authority (SFDA).
- Member of National Advisory Committee of Health Economics (Saudi Health Council)
- Chair, Local Content Committee (NGHA).
- Chair, Wasfaty Implementation Committee (NGHA-NUPCO)
- Chair, Cost-Efficiency Committee (NGHA)
- Member, Spending Efficiency Program (Ministry of National Guard)
- Member of the Corporate Pharmacy and Therapeutics Committee and all P&T subcommittees at NGHA: Corporate Oncology Pharmaceutical Subcommittee, Corporate Drug Evaluation Subcommittee, Corporate Antimicrobial Subcommittee.
- Member of Procurement Committee (NUPCO)

- Member of the Drug Expenditure Committee (NGHA).
- Member of the Saudi Scientific Society of Blood & Marrow Transplantation
- Member of ISPORE (International Society for Pharmacoeconomics and Outcomes Research) Saudi Chapter.

List of publications

- **2023- Journal articles**

- Alanizi M,Alajlan S,Al-Abdulkarim H, Efficacy and cost-impact analysis of B-lactam/Macrolide Therapy antibiotics in the treatment of upper respiratory Tract Infections in the emergency department (2023) GLOBAL JOURNAL ON QUALITY AND SAFETY IN HEALTHCARE(2023) pp-1-2 [DOI](#) [MTMT](#)
- Al-Jedai AH,Lomas J,Almudaiheem HY,Al-Ruthia YS,Alghamdi S,Awad N,Alghamdi A,Alowairdhi MA,Al-Abdulkarim H,Almadi M,Bunyan RF,Ochalek J, Informing a cost-effectiveness threshold for Saudi Arabia (2023) JOURNAL OF MEDICAL ECONOMICS(26) pp-128-138 [DOI](#) [MTMT](#)
- Al-Omar HA,Alshehri A,Abanumay A,Al-Abdulkarim H,Alrumaih A,Eldin MS,Alqahtani SA, The Impact of Obesity in Saudi Arabia: Healthcare Resource Use and Costs Associated with Obesity-Related Complications (2023) ADVANCES IN THERAPY() pp- [DOI](#) [MTMT](#)
- Alqahtani SA,Al-Omar HA,Alshehri A,Abanumay A,Al-Abdulkarim H,Alrumaih A,Eldin MS,Schnecke V, Obesity Burden and Impact of Weight Loss in Saudi Arabia: A Modelling Study (2023) ADVANCES IN THERAPY() pp- [DOI](#) [MTMT](#)
- Elezbawy B,Fasseeh AN,Fouly E,Tannira M,Dalle H,Aderian S,Abu EL,Al-Abdulkarim H,Ammoury A,Altawil E,Al TA,Albreiki F,Al-Haddab M,Al-Lafi A,Alowayesh M,Al-Sheikh A,Elsayed M,Elshamy A,Eshmawi M,Farag A,Hamadah I,Hedibel M,Kannenbergs S,Karam R,Metni M,Raboobee N,Steinhoff M,Abaza S,Farghaly M,Kaló Z, Humanistic and Economic Burden of Atopic Dermatitis for Adults and Adolescents in the Middle East and Africa Region (2023) DERMATOLOGY AND THERAPY(13) pp-131-146 [DOI](#) [MTMT](#)
- Menyafah QA,Sami A,Al-Abdulkarim H,Maha A,Mohammed A,Muneerah A,Muneerah A,Mai DA,Maha A,Njla Q,Salih BS, Assessment of quality of life in patients with Upper respiratory tract infection using EQ-5D-5L (2023) GLOBAL JOURNAL ON QUALITY AND SAFETY IN HEALTHCARE(2023) pp-3-4 [MTMT](#)

- **2022- Journal articles**

- Al-Abdulkarim H,Almodaimegh H,Abu Esba LC,Sharma Y,Attar S,Hussain W,Alhomood I,Al-Omari BA,Mohamed O,Alsaqa'aby M,Roshdy A,Anwar A,Hamad T,Alzahrani Z, COST-EFFECTIVENESS ANALYSIS OF UPADACITINIB AS A TREATMENT OPTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS IN KINGDOM OF SAUDI ARABIA (2022) VALUE IN HEALTH(25) pp-S407-S407 [MTMT](#)
- AlRuthia Y,Al-Salloum HF,Almohammed OA,Alqahtani AS,Al-Abdulkarim H,Alsofayan YM,Almudarra SS,AlQahtani SH,Almutlaq A,Alabdulkareem K,Balkhi B,Almutairi HT,Alanazi AS,Asiri YA, Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia (2022) VACCINES (BASEL)(10) pp- [DOI](#) [MTMT](#)
- AlRuthia Y,Bahari OH,Alghnam S,Alrumaih AM,Asiri H,Alshammari M,Alhowimel M,Al-Abdulkarim H, Real-World Impact of Switching From Insulin Glargine (Lantus (R)) to Basaglar (R) and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia (2022) FRONTIERS IN PUBLIC HEALTH(10) pp- [DOI](#) [MTMT](#)
- Elezbawy B,Fasseeh AN,Fouly E,Esba LC,Al-Abdulkarim H,Al-Haddab M,Al-Sheikh A,Altawil E,Al Turaiki A,Eshmawi M,Hamadah I,Tannira M,Dalle H,Aderian S,Roshdy A,Jaheen A,Hamad T,Abaza S,Kaló Z, The humanistic and economic burden of atopic dermatitis among adults and adolescents in Saudi Arabia (2022) JOURNAL OF MEDICAL ECONOMICS(25) pp-1231-1239 [DOI](#) [MTMT](#)
- Ismail S,Abu Esba L,Khan M,Al-Abdulkarim H,Modimagh H,Yousef C, An Institutional Guide for Formulary Decisions of Biosimilars (2022) HOSPITAL PHARMACY(58) pp-38-48 [DOI](#) [MTMT](#)
- Malkin JD,Baid D,Alsukait RF,Alghaith T,Alluhidan M,Al-Abdulkarim H,Altowajiri A,Almalki ZS,Herbst CH,Finkelstein EA,El-Saharty S,Alazemi N, The economic burden of overweight and obesity in Saudi Arabia (2022) PLOS ONE(17) pp-e0264993 [DOI](#) [MTMT](#)
- Motahari Nezhad H,Al-Abdulkarim H,Fgaier M,Abid MM,Péntek M,Gulácsi L,Zrubka Z, Digital Biomarker-Based Interventions. Systematic Review of Systematic Reviews (2022) JOURNAL OF MEDICAL INTERNET RESEARCH(24) pp- [DOI](#) [MTMT](#)

Zrubka Z,Péntek M,Mhanna L,Fgaier M,Al-Abdulkarim H,El-Dahiyat F,Drummond M,Gulácsi L, Accuracy of Transferred Medical Costs: Evidence from the Middle East and North Africa Region (2022) VALUE IN HEALTH(25) pp-S433 [DOI](#) [MTMT](#)

Zrubka Z,Péntek M,Mhanna L,Abu-Zahra T,Mahdi-Abid M,Fgaier M,El-Dahiyat F,Al-Abdulkarim H,Drummond M,Gulácsi L, Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability (2022) PHARMACOECONOMICS(40) pp-587-599 [DOI](#) [MTMT](#)

- **2022- Other publications**

Al-Abdulkarim H, Outcomes of continuous glucose monitoring: Protocol for A Systematic Review of Systematic Reviews (2022) IEEE 20th Jubilee International Symposium on Intelligent Systems and Informatics (SISY 2022)() pp-37-40 [MTMT](#)

Motahari Nezhad H,Fgaier M,Al-Abdulkarim H, Methodological and bibliometric examination of systematic reviews of digital biomarkerbased studies (2022) IEEE 20th Jubilee International Symposium on Intelligent Systems and Informatics (SISY 2022)() pp-47-52 [MTMT](#)

2021- Journal articles

Abu Esba LC,Yousef C,Ismail S,Halim M,Almodaimagh H,Al-Abdulkarim H,Alhowimel M, Fixed dose combinations: A formulary decision guide (2021) HEALTH POLICY AND TECHNOLOGY(10) pp-100500 [DOI](#) [MTMT](#)

Alkhudair N,Alshamrani M,Samarkandi H,Almodaheem H,Al-Abdulkarim H,Alsaqaaby M,Alnajjar F,Alhashem H,Bakkar M,Bazarbashi S,Alnahedh M,Alfraih F,Alawagi M,Al-jedai A, Cancer Management in Saudi Arabia: Recommendations by the Saudi Oncology HeAlth Economics ExpeRt GrouP (SHARP) (2021) SAUDI PHARMACEUTICAL JOURNAL(29) pp-115-120 [DOI](#) [MTMT](#)

AlRuthia Y,Alrashed SA,Balkhi B,Aljamal MS,Alsifri S,Alrumaih AM,Alsabaan F,Alsaqa'aby M,Al-Abdulkarim H,Altowaijri AI, COVID-19 and Saudi Arabia public financing of prescription drugs: An opportunity for reform (2021) HEALTH POLICY AND TECHNOLOGY(10) pp-3-6 [DOI](#) [MTMT](#)

- **2020- Journal articles**

Abu Esba LC,Al-Abdulkarim H,Alrushidan A,Al Harbi M, Pharmacy and Therapeutics Committee Preparedness Plan for COVID-19 (2020) GLOBAL JOURNAL ON QUALITY AND SAFETY IN HEALTHCARE(3) pp-55-64 [DOI](#) [MTMT](#)

Menyfah QA,Al-Abdulkarim H,Sami AA,Abdul RJ, Immunotherapy Prescribing Patterns in the Oncology Department of a Tertiary Care Hospital: A Retrospective Study in Riyadh, Saudi Arabia (2020) Fourth Annual International Forum for Quality Cancer Care (IFQCC2020) Abstracts() pp-S14-S15 [MTMT](#)

Zrubka Z,Al-Abdulkarim H, Guidelines for Pharmacoeconomic Evaluations (2020) VALUE IN HEALTH(23) pp-83-101 [DOI](#) [MTMT](#)

- **2019- Journal articles**

Al-Abdulkarim H,Garcia Uranga J,Bawazir O, ONCE-WEEKLY SEMAGLUTIDE COMPARED TO OTHER TWO GLP1-RAS AVAILABLE IN THE PUBLIC HEALTHCARE SYSTEM IN THE KINGDOM OF SAUDI ARABIA: A RELATIVE COST OF CONTROL ANALYSIS (2019) VALUE IN HEALTH(22) pp-S576-S577 [DOI](#) [MTMT](#)

Jazieh AR,Pizzo E,Gulácsi L,Eldahiyat F,Abu-Helalah M,Ibrahim N,Al-Abdulkarim H,Maraiki F,AlSaggabi A,Cornes P, Implementation of Country-Wide Pharmacoeconomic Principles in Cancer Care in Developing Countries: Expert-Based Recommendations (2019) GLOBAL JOURNAL ON QUALITY AND SAFETY IN HEALTHCARE(2) pp-109-114 [DOI](#) [MTMT](#)

- **2018- Journal articles**

Jazieh AR,Ibrahim N,Al-Abdulkarim H,Maraiki F,Alsaleh K,Thill M, Expert-Based Strategies to Improve Access to Cancer Therapeutics at the Hospital Level (2018) GLOBAL JOURNAL ON QUALITY AND SAFETY IN HEALTHCARE(1) pp-6-12

[DOI](#) [MTMT](#)